Related Experiment Video

Updated: Jun 6, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K

A novel micropeptide miPEP205 suppresses the growth and metastasis of TNBC

Zheng Zhang1, Fanrong Li1, Xiaoxiao Dai2

  • 1Department of Genetics, Medical College of Soochow University, Suzhou, 215123, China.

Oncogene
|December 2, 2024
PubMed

Insights

A novel micropeptide, miPEP205, derived from a long non-coding RNA, effectively inhibits triple negative breast cancer (TNBC) growth and metastasis. This micropeptide shows promise as a new therapeutic target for TNBC, offering hope for improved patient outcomes.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Triple negative breast cancer (TNBC) is an aggressive subtype with limited treatment options.
  • High recurrence rates necessitate the development of novel therapeutic strategies for TNBC.
  • Long non-coding RNAs (lncRNAs) are emerging as key regulators in various cancers.

Purpose of the Study:

  • To identify and characterize novel therapeutic targets for triple negative breast cancer.
  • To investigate the role of lncRNA-derived micropeptides in TNBC progression.
  • To evaluate the therapeutic potential of miPEP205 in preclinical models of TNBC.

Main Methods:

  • Identification and characterization of miPEP205, a micropeptide derived from lncRNA MIR205HG.
  • Analysis of miPEP205 expression in clinical TNBC samples.
  • Mechanistic studies involving EGR3, GSK-3β, and β-catenin signaling.
  • In vivo experiments using the MMTV-PyMT spontaneous breast cancer mouse model.

Main Results:

  • miPEP205 significantly inhibits TNBC cell growth and metastasis in vitro and in vivo.
  • Down-regulation of miPEP205 expression correlates with poor prognosis in TNBC patients.
  • miPEP205 targets the GSK-3β/β-catenin pathway by promoting GSK-3β phosphorylation.
  • Gene introduction or exogenous administration of miPEP205 reduces tumor burden and metastasis in mice, improving survival.

Conclusions:

  • miPEP205 is a novel, potent antitumor agent derived from a lncRNA.
  • miPEP205 represents a promising therapeutic candidate for triple negative breast cancer.
  • Targeting miPEP205 offers a potential new avenue for TNBC treatment.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.8K
Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence06:52

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Published on: November 5, 2021

3.0K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K